{"schema_version":"1.0","type":"article","title":"Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.md","lang":"en","date":"2026-06-17","publish_at":"2026-06-17T09:30:00+08:00","updated_at":"2026-06-17","category":"商業分析系列","topic":"商業分析系列","tags":["GLP-1","Ecnoglutide","Wegovy","Pfizer","Novo Nordisk","Obesity medicine"],"summary":"Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Head-to-head signal","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-01.png"},{"alt":"What really matters","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-02.png"},{"alt":"Wegovy moat","url":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-17）。Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King。https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}